Both companies may succeed in this industry.

The company got some bad news to start 2026.

Eli Lilly (LLY) has drawn fresh attention after recent price moves, with the share closing at $1,038.40. Short term returns ...

Shares of Eli Lilly came under selling pressure following an announcement by the U.S. Food and Drug Administration (FDA) ...

At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...

A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." Third-Quarter Reported Results In Q3 ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech Abivax and had no contact with U.S. pharmaceutical giant Eli Lilly, ...

The MarketWatch News Department was not involved in the creation of this content. -- Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. -- Increased ...

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range ...